吡柔比星与丝裂霉素C膀胱灌注预防TURBT术后浅表性膀胱尿路上皮癌复发的临床研究  

Clinical research on prevention of recurrence of superficial bladder cancer by intravesical instillation of pirarubicin or mitomycin C after transurethral resection of bladder tumor

作　　者：滕东海[1] 张雁钢[2] 王晓锋[1] 李军[1] 黄贵闽[1] 敖敏[1] 杜友怀 

机构地区：[1]四川省乐山市人民医院泌尿外科,乐山614000 [2]山西医科大学第一临床医学院泌尿外科

出　　处：《山西医科大学学报》2011年第4期341-343,共3页Journal of Shanxi Medical University

摘　　要：目的评价吡柔比星(THP)和丝裂霉素C(MMC)膀胱灌注预防经尿道膀胱肿瘤切除(TURBT)术后浅表性膀胱尿路上皮癌复发的临床效果和安全性。方法将2008-01～2010-12收治的80例TURBT术后浅表性膀胱尿路上皮癌患者按照入组顺序采用区组随机法随机分为2组,每组40例,分别接受THP和MMC膀胱灌注治疗。随访12-36个月,观察膀胱尿路上皮癌的复发情况和药物不良反应。结果 THP组和MMC组的膀胱尿路上皮癌复发率分别为15.0%和17.5%,两组差异无统计学意义(P>0.05)。THP组和MMC组化学性膀胱炎发生率分别为42.5%和30%,两组差异有统计学意义(P<0.05)。THP组和MMC组均无尿道狭窄、白细胞减少和肝肾功能损害病例。结论 THP和MMC用于预防TURBT术后浅表性膀胱尿路上皮癌复发临床效果相当,不良反应小,无全身性药物反应。Objective To evaluate the effectiveness and safety of intravesically instilling pirarubicin（THP） and mitomycin C（MMC） after transurethral resection of bladder tumor（TURBT） of superficial bladder cancer in prevention of tumor recurrence.Methods Eighty patients of superficial bladder cancer after TURBT were divided into 2 groups with randomized block design（40 cases in each group）.The patients received intravesical treatment with THP and MMC in 2 groups,respectively.All patients were followed up for 12-36 months,and the recurrence rate and adverse reactions were recorded.Results Recurrence rate was 15.0% for THP and 17.5% for MMC,and the difference was not significant statistically（P〉0.05）.The incidence rates of chemical cystitis were 42.5% in THP group and 30% in MMC group（P〈0.05）.No urethral stricture,leukopenia and liver and kidney dysfunction were observed in both groups.Conclusion THP and MMC have the similar efficacy in prevention of recurrence of superficial bladder cancer by intravesical instillation after TURBT.The adverse drug reactions are tolerable and no systemic reaction is observed.

关 键 词：吡柔比星 丝裂霉素C 膀胱灌注 膀胱尿路上皮癌 

分 类 号：R737.14[医药卫生—肿瘤]